Functional dyspepsia Medical Services in China

Functional dyspepsia (FD) is a chronic, heterogeneous disorder of the upper gastrointestinal tract characterized by persistent or recurrent epigastric pain or discomfort—such as burning, early satiety, postprandial fullness, or nausea—in the absence of structural, biochemical, or metabolic abnormalities that could explain the symptoms. It is classified under disorders of gut–brain interaction (formerly functional gastrointestinal disorders) and diagnosed using Rome IV criteria after excluding organic causes like peptic ulcer disease, gastric cancer, gastroesophageal reflux disease (GERD), celiac disease, or Helicobacter pylori infection via endoscopy, serology, breath testing, or histopathology. Pathophysiologically, FD involves complex interplay among visceral hypersensitivity, impaired gastric accommodation and motility (e.g., delayed gastric emptying or antral hypomotility), low-grade mucosal inflammation, altered gut microbiota composition, and central nervous system dysregulation—including heightened perception of normal gastric signals and stress-modulated autonomic and neuroendocrine responses. Psychosocial factors such as anxiety, depression, somatization, and early-life adversity further modulate symptom expression and severity. Epidemiologically, FD affects approximately 10–20% of the global adult population, with regional variation: prevalence in China ranges from 8% to 15%, based on community-based surveys using validated questionnaires. It is more common in women (female-to-male ratio ~1.5:1) and peaks in the third to fifth decades of life. Key risk factors include prior acute gastroenteritis (post-infectious FD), H. pylori infection (even after eradication), smoking, frequent NSAID use, high psychological distress, and dietary triggers (e.g., fatty, spicy, or acidic foods). Unlike organic diseases, FD carries no increased mortality risk—but its chronic, fluctuating nature profoundly impairs quality of life. Patients report significant reductions in work productivity (presenteeism and absenteeism), disrupted sleep, social withdrawal, diminished physical activity, and higher healthcare utilization. Many experience treatment frustration due to symptom recurrence and limited response to conventional therapies, contributing to anxiety about undiagnosed malignancy and reduced health-related quality of life scores comparable to those seen in inflammatory bowel disease or moderate asthma. Early multidisciplinary management—including dietary counseling, pharmacotherapy, cognitive-behavioral strategies, and patient education—is essential to restore functional capacity and prevent long-term disability.

Functional dyspepsia (FD) is a chronic, heterogeneous disorder characterized by persistent or recurrent epigastric discomfort—including postprandial fullness, early satiation, epigastric pain, or burning—in the absence of structural, metabolic, or systemic disease that explains the symptoms. Diagnosed using Rome IV criteria after excluding organic pathology (e.g., peptic ulcer disease, gastric malignancy, celiac disease, or biliary tract disorders) via upper endoscopy, abdominal ultrasound, and appropriate laboratory testing, FD affects approximately 15–20% of the global population and imposes substantial socioeconomic burden. Management is individualized, symptom-driven, and grounded in a biopsychosocial model—emphasizing patient education, lifestyle modification, pharmacotherapy, and psychosocial support. Surgical intervention has no role in FD, as it is not an anatomical or obstructive disorder.

Conservative treatment forms the cornerstone of FD management. First-line strategies include dietary counseling: patients are advised to eat smaller, more frequent meals; avoid known triggers such as fatty foods, caffeine, carbonated beverages, spicy foods, and alcohol; and maintain regular meal timing to stabilize gastric motility and reduce visceral hypersensitivity. Weight optimization is recommended for overweight or obese individuals, as adiposity correlates with low-grade gastric inflammation and delayed gastric emptying. Smoking cessation is strongly encouraged due to nicotine’s inhibitory effect on lower esophageal sphincter pressure and gastric accommodation. Stress reduction techniques—including cognitive behavioral therapy (CBT), mindfulness-based stress reduction (MBSR), and gut-directed hypnotherapy—are evidence-based adjuncts shown to improve symptom severity and quality of life in randomized controlled trials. Patient education is critical: clinicians should explain the benign nature of FD, clarify the absence of cancer risk, and normalize symptom fluctuations to mitigate health anxiety and reduce unnecessary diagnostic repetition.

Pharmacologic therapy is initiated when conservative measures fail or symptoms significantly impair daily functioning. Prokinetic agents remain first-line for predominant motility-related symptoms (e.g., postprandial fullness, early satiation). Acotiamide—a reversible acetylcholinesterase inhibitor approved in Japan and increasingly used off-label in China and Europe—enhances gastric accommodation and accelerates gastric emptying with favorable tolerability. Domperidone (where available and appropriately monitored for cardiac safety) and low-dose erythromycin (a motilin receptor agonist) are alternatives, though erythromycin use is limited by tachyphylaxis. For epigastric pain or burning, acid-suppressive therapy is empirically trialed despite normal endoscopic findings: proton pump inhibitors (PPIs) at standard doses (e.g., omeprazole 20 mg once daily) for 4–8 weeks demonstrate modest but statistically significant benefit over placebo in meta-analyses, particularly in patients with overlapping gastroesophageal reflux symptoms or histologic evidence of low-grade gastric inflammation. H2-receptor antagonists may be considered for milder cases or PPI intolerance. Antidepressants—specifically low-dose tricyclic antidepressants (TCAs) like amitriptyline (10–25 mg at bedtime) or selective serotonin reuptake inhibitors (SSRIs)—are indicated for refractory FD with comorbid anxiety, depression, or central sensitization. These agents modulate descending pain inhibition pathways and improve visceral perception independent of mood effects. Emerging therapies under investigation include potassium-competitive acid blockers (P-CABs) and novel 5-HT4 receptor agonists, though none are yet FDA- or NMPA-approved specifically for FD.

Surgical treatment has no established indication in functional dyspepsia. Unlike mechanical obstruction or neoplastic disease, FD lacks surgically correctable pathology. Procedures such as fundoplication, pyloroplasty, or gastric resection are contraindicated and carry unacceptable risks—including dumping syndrome, bile reflux, nutritional deficits, and persistent symptoms—without evidence of efficacy. Misdiagnosis leading to unnecessary surgery remains a serious iatrogenic concern; thus, rigorous exclusion of organic disease and multidisciplinary reassessment are mandatory before considering any invasive intervention.

China offers distinct advantages in FD management, rooted in integrated clinical infrastructure and evolving evidence-based practice. Major tertiary hospitals—such as Peking Union Medical College Hospital, Zhongshan Hospital (Fudan University), and West China Hospital—employ standardized Rome IV–based diagnostic protocols, high-resolution manometry, and gastric emptying scintigraphy for phenotyping (e.g., postprandial distress syndrome vs. epigastric pain syndrome). Acotiamide is widely accessible and reimbursed under China’s National Reimbursement Drug List, facilitating early prokinetic use. Traditional Chinese Medicine (TCM) integration is uniquely robust: evidence-informed TCM patterns (e.g., liver-stomach disharmony, spleen-stomach deficiency) guide personalized herbal formulas (e.g., Xiangsha Liujunzi Tang or Banxia Xiexin Tang), acupuncture at ST36 (Zusanli), PC6 (Neiguan), and auricular therapy—all supported by RCTs demonstrating synergistic symptom reduction when combined with conventional care. Furthermore, China’s national FD registry and multicenter studies (e.g., the CHINA-FD cohort) accelerate real-world data generation, informing local guidelines updated annually by the Chinese Society of Gastroenterology.

Recovery advice emphasizes long-term self-management and realistic expectations. Patients should understand FD is often chronic but controllable—not curable—and symptom remission may fluctuate. A symptom diary tracking food intake, stressors, sleep, and symptom intensity helps identify personal triggers and assess treatment response. Regular physical activity (≥150 min/week moderate-intensity exercise) improves autonomic balance and gastric motility. Sleep hygiene—consistent bedtime, avoidance of late-night meals, and elevation of head-of-bed—is essential, given the bidirectional relationship between sleep disruption and visceral hypersensitivity. Follow-up intervals should be tailored: stable patients every 3–6 months; those initiating new medications or psychological interventions every 4–8 weeks. Referral to dietitians, clinical psychologists, or TCM practitioners is encouraged for multimodal support. Finally, patients must be counseled to avoid self-medication with NSAIDs or unregulated supplements, which may exacerbate mucosal irritation or drug interactions. With comprehensive, patient-centered care, >70% of individuals achieve meaningful symptom improvement and restored functional capacity within 6–12 months.